Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- NEW PRODUCTS IN BRIEF
December 23, 2002
- Bill on New Drug Organization Clears the Diet
December 23, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
December 23, 2002
- No Meaningful Progress on Mutual Recognition: MOSS Follow-up Talks
December 23, 2002
- OTC NEWS IN BRIEF
December 23, 2002
- Sanofi-Synthelabo to Further Boost Investment in Japan in 2003
December 16, 2002
- Sanus, Honma Toho: Return to the Black with Improved Profitability
December 16, 2002
- Bayer Biological Products to License IVIG Production Technology to JRC
December 16, 2002
- Tax Deduction from Total Clinical Research Cost to Be Allowed
December 16, 2002
- Novartis Aims For 10% Statin Market Share for Lochol
December 16, 2002
- Ando Chemical Works: Sales Post 6% Increase
December 16, 2002
- REGULATORY NEWS IN BRIEF
December 16, 2002
- Kissei Licenses KUC-7483 to Boehringer Ingelheim
December 16, 2002
- Hokuyaku: Profits Jump with Slight Increase in Sales
December 16, 2002
- Allow For-profit Corporations to Operate Medical Facilities: JPMA Forum
December 16, 2002
- Asahi Kasei Aims For \200 Bil. Sales for Health Care Business
December 16, 2002
- Proposal of Designation of Bio-derived Products at the Final Stage
December 16, 2002
- Toyama Accelerates Development of T-3811
December 16, 2002
- Nihon Rinsho Yakuri Kenkyusho to Tie Up with Americas Doctor
December 16, 2002
- Report Compiled on Definition of SMOs: Korosho Panel
December 16, 2002
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…